NCT06568861

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

← Hub

Registry fields

Overall status: COMPLETED
Conditions: COVID-19
Study type: INTERVENTIONAL
Phase: PHASE1
Primary purpose: TREATMENT
Intervention type: DRUG
Interventions: ALG-097558
Lead sponsor: Aligos Therapeutics (INDUSTRY)

Cached at: 2026-08-06 08:28:28

View on ClinicalTrials.gov

Brief summary

This is a Phase 1 non-randomized, open-label, multiple dose, parallel-group study of ALG-097558 in subjects with moderate hepatic impairment and subjects without hepatic impairment, matched for age, body weight and, to the extent possible, for gender. The primary purpose of this study is to characterize the effect of hepatic impairment on the plasma pharmacokinetics of ALG-097558 following administration of multiple, twice daily (Q12H) oral (PO) doses.

Contact

Need a report or Korean medical writing based on this trial?

Request a report Medical writing Custom research report